1-2 of 2
Michael Craig
Close
Sort by
Journal Articles

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Clinical Trials & Observations
Jessica K. Altman, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota, Michael Keng, Olga Frankfurt, Yasmin Abaza, Dale L. Bixby, Ashkan Emadi, Micah Burch, Bhavana Bhatnagar, Selina M. Luger, Mary-Elizabeth Percival, Ofir Wolach, Michael Craig, Chezi Ganzel, Gail Roboz, Itai Levi, Anna Gourevitch, Liat Flaishon, Shoshi Tessler, Chen Blumberg, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7494–7500.
https://doi.org/10.1182/bloodadvances.2023010943
Published: 2023
Journal Articles

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells

Clinical Trials & Observations
Yi-Bin Chen, Jennifer Le-Rademacher, Ruta Brazauskas, Deidre M. Kiefer, Mehdi Hamadani, John F. DiPersio, Mark R. Litzow, Michael Craig, Mitchell E. Horwitz, Andrew S. Artz, Brian L. McClune, Hugo F. Fernandez, Hien Kim Duong, Hati Kobusingye, Mandi Proue, Rebecca J. Drexler, Mary M. Horowitz, Bronwen E. Shaw, John P. Miller, Sakura Hosoba, Edmund K. Waller, Steven M. Devine
Journal: Blood Advances
Blood Adv (2019) 3 (6): 875–883.
https://doi.org/10.1182/bloodadvances.2018027599
Published: 2019
Includes: Supplemental data